查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018546

核子医学市场：2026-2032年全球市场预测（依产品类型、给药途径、应用、应用领域及最终用户划分）

Nuclear Medicine Market by Product Type, Mode Of Administration, Usage, Application, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核医市场价值将达到 160.5 亿美元，到 2026 年将成长至 177.2 亿美元，到 2032 年将达到 338.7 亿美元，复合年增长率为 11.25%。

主要市场统计数据
基准年 2025 160.5亿美元
预计年份：2026年 177.2亿美元
预测年份 2032 338.7亿美元
复合年增长率 (%) 11.25%

核子医学发展趋势：推动全球医疗保健进步的现代诊断和治疗创新基础性见解

核子医学已成为现代医学的基石，它利用放射性同位素的独特特性，实现了精准诊断和标靶治疗。从早期的伽马摄影机成像到如今先进的治疗诊断学一体化（诊断治疗）方法，核医学领域不断发展，以满足日益增长的个人化医疗需求，并受益于分子生物学的进步以及成像设备和放射性药物化学的持续创新。整个价值链上的相关人员——放射性药物研发人员、设备製造商、临床医生和监管机构——都在应对不断变化的临床指南、不断扩大的适应症以及日益严格的安全性和供应保障审查所带来的挑战。

从传统的同位素方案到跨多种模式的突破性放射性药物开发，识别正在重塑核子医学的变革性变化。

核子医学领域正经历一场变革，这主要得益于放射性药物发现的突破性进展和技术创新的整合。近年来，针对特定生物标记的新型分子示踪剂层出不穷，使临床医生能够以前所未有的灵敏度检测病理过程。同时，数位成像检测器和先进的断层重建演算法不断提升影像解析度和定量分析能力。这两大趋势正朝着融合正子断层扫描（PET）、单光子发射电脑断层扫描（SPECT）和电脑断层扫描（CT）的混合平台发展，从而提供更全面的疾病观点。

评估 2025 年美国关税对核医供应链、研究合作趋势及放射性药物跨境贸易流量的累积影响。

美国在2025年实施的关税政策为核医供应链带来了新的复杂性，影响了同位素材料和影像设备的进口。随着关键原材料和特殊零件关税的生效，製造商面临日益增长的生产成本压力和物流限制。为了因应这些变化，一些生产商正在调整筹资策略，投资建造国内同位素生产设施，并寻求垂直整合以减轻进口关税的影响。

透过对产品类型、给药方法、应用类别、临床应用和最终用户概况等关键市场细分进行深入分析，以明确策略方向。

市场区隔洞察揭示了一个支持策略规划和资源分配的多面向框架。按产品类型划分，该行业可分为诊断放射性药物（包括正电子发射断层扫描 (PET) 和单光子发射电脑断层扫描 (SPECT) 同位素）和治疗性核医学（包括使用 α 和 β 发射体的放射性药物疗法，以及用于近距离放射治疗的同位素，例如铯-131、碘-125、铱-192 和铯-1923）。这种多层次的分类有助于临床效用、生产复杂性和监管路径进行针对性分析。

为了在核子医学业务扩大策略中做出明智的决策，我们分析了美洲、欧洲、中东和非洲以及亚太市场的区域趋势和优先驱动因素。

核子医学领域的区域发展趋势反映了美洲、欧洲、中东和非洲以及亚太地区在投资模式、基础设施成熟度和法规环境的差异。在美洲，成熟的北美医疗保健系统正在推动先进影像平台和尖端放射性追踪剂的应用，而拉丁美洲市场则专注于扩展基础PET和SPECT功能，以满足日益增长的诊断需求。该地区的相关人员正在努力平衡成本效益高的供应解决方案与对现代治疗诊断学方案的需求。

分析推动核子医学价值链创新、卓越营运和竞争优势的关键产业相关人员和策略伙伴关係。

主要企业正积极建立策略联盟，以加速产品线开发并巩固市场地位。全球影像设备製造商正与放射性药物研发公司合作，共同开发端到端解决方案，以优化新型示踪剂的扫描器效能。专业同位素生产商正与合约研发生产机构 (CDMO) 合作，扩大靶向α和β发射体的产量；同时，核医药局正透过与医院和诊断中心签订许可协议来拓展业务。

为帮助产业领导者优化供应链、确保合规性以及优先考虑核医生态系统内的投资提供切实可行的建议。

产业领导者应优先考虑透过投资区域生产能力和建立联盟式供应协议来实现同位素来源多元化，以此对冲地缘政治风险和贸易中断。积极参与标准化机构，加强与监管机构的合作，将有助于提高关键市场核准流程的一致性，并缩短新化合物进入临床试验的时间。此外，将先进的数据分析技术整合到采购和库存管理中，将提高预测准确性，并最大限度地减少半衰期短的同位素的浪费。

详细介绍为确保核医市场情报的数据完整性、全面的市场分析和可靠的检验而采用的严格调查方法。

本报告的洞见是基于严谨的调查方法，结合了第一手和第二手研究、资料三角验证以及专家检验。对同行评审文章、专利申请和监管资料库的广泛查阅构成了报告的基础知识库。此外，报告还对放射性药物生产商、影像设备供应商、学术研究中心和监管机构的高管进行了深入访谈，以获取关于新兴趋势和行业挑战的第一手观点。

总结主要研究结果和策略意义，供相关人员参考，以利用新趋势并塑造核子医学产业的未来。

先进示踪剂的研发、数位影像技术的突破以及不断演进的法规结构的融合，正将核医学转变为一个真正以精准为导向的领域。从2025年关税对供应链韧性的影响，到不同产品类型和临床应用领域细緻细分市场的深入分析，本分析强调了策略适应性和协同创新的重要性。区域趋势进一步凸显了采取在地化方法的必要性，这些方法应着眼于本地基础设施、监管协调和市场成熟度。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 核子医学市场：依产品类型划分

  • 诊断用放射性药物
    • 正子断层扫描（PET）同位素
    • 单光子发射电脑断层扫描（SPECT）用同位素
  • 治疗性核子医学
    • 用于近距离放射的同位素
      • 铯-131
      • 碘-125
      • 铱-192
      • 钯-103
    • 放射性药物疗法
      • α粒子发射材料
      • β射线放射体

第九章 依给药方式分類的核医市场

  • 静脉注射
  • 口服

第十章 核子医学市场依应用领域划分

  • 诊断治疗
    • PET扫描仪
      • 模拟PET
      • 数字PET
    • SPECT扫描仪
  • 治疗

第十一章 核子医学市场：依应用领域划分

  • 循环系统
  • 内分泌学
  • 胃肠病学
  • 神经病学
  • 肿瘤学
  • 整形外科
  • 呼吸内科

第十二章 核子医学市场：依最终用户划分

  • 学术和研究机构
  • 诊断中心
  • 医院
    • 公立医院
    • 私立医院

第十三章 核子医学市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 核子医学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 核子医学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国核子医学市场

第十七章：中国核医市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3B Pharmaceuticals GmbH
  • Actinium Pharmaceuticals, Inc.
  • BJ Madan & Co.
  • Bayer AG
  • Bracco SpA
  • BWX Technologies, Inc.
  • Clarity Pharmaceuticals
  • Curium
  • Eli Lilly and Company
  • GE HealthCare
  • IBA
  • Institute of Isotopes Co., Ltd
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Medi-Radiopharma Co., Ltd.
  • Nordion
  • Northstar Medical Technologies LLC
  • Novartis AG
  • Nusano, Inc.
  • PeptiDream Inc.
  • Radiopharm Theranostics Limited
  • SHINE Technologies, LLC
  • Siemens Healthineers AG
  • Sinotau Pharmaceuticals Group
  • South African Nuclear Energy Corporation
  • State Atomic Energy Corporation Rosatom
  • Thor Medical AS by Nordic Nanovector ASA
Product Code: MRR-A339DAEFAF4C

The Nuclear Medicine Market was valued at USD 16.05 billion in 2025 and is projected to grow to USD 17.72 billion in 2026, with a CAGR of 11.25%, reaching USD 33.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.05 billion
Estimated Year [2026] USD 17.72 billion
Forecast Year [2032] USD 33.87 billion
CAGR (%) 11.25%

Navigating the Evolving Nuclear Medicine Landscape: Foundational Insights Into Modern Diagnostics and Therapeutic Innovations Driving Global Healthcare Progress

Nuclear medicine has emerged as a cornerstone of modern healthcare, harnessing the unique properties of radioisotopes to enable both precise diagnostics and targeted therapies. From early gamma camera imaging to today's sophisticated theranostic approaches, the field has evolved in response to rising demand for personalized care, advances in molecular biology, and relentless innovation in imaging hardware and radiopharmaceutical chemistry. Stakeholders across the value chain-including radiopharmaceutical developers, equipment manufacturers, clinical practitioners, and regulators-are navigating a landscape shaped by shifting clinical guidelines, expanding indications, and heightened scrutiny of safety and supply security.

Against this backdrop, the convergence of digital imaging technologies, novel tracer development, and integrated data analytics is catalyzing a new era of nuclear medicine. Technological strides such as high-resolution detectors, digital positron emission tomography, and hybrid imaging platforms are amplifying diagnostic accuracy, while breakthroughs in targeted alpha and beta emitters are unlocking therapeutic options for oncology, cardiology, and neurology. This introduction lays the foundation for an in-depth exploration of the forces reshaping nuclear medicine, setting the stage for a detailed examination of market drivers, segmentation insights, regional dynamics, and strategic imperatives that will define the industry's trajectory through 2025 and beyond.

Identifying Transformational Shifts Reshaping Nuclear Medicine From Traditional Isotope Protocols to Breakthrough Radiopharmaceutical Developments Across Multiple Modalities

The nuclear medicine landscape is undergoing transformative shifts, originating from breakthroughs in radiopharmaceutical discovery and convergent technological innovations. Recent years have witnessed a surge in novel molecular tracers tailored to specific biomarkers, enabling clinicians to detect pathological processes with unprecedented sensitivity. Concurrently, digital imaging detectors and advanced tomographic reconstruction algorithms have elevated image resolution and quantification capabilities. These dual trends are converging in hybrid platforms that seamlessly integrate positron emission tomography, single photon emission computed tomography, and computed tomography, fostering a more holistic view of disease.

Beyond hardware and tracer advances, the industry is responding to evolving regulatory frameworks that emphasize safety, standardization, and harmonized licensing across jurisdictions. Governments and international bodies are working to streamline radiopharmaceutical approval pathways and improve cross-border supply arrangements, while also enforcing stringent quality controls for isotope production and handling. This regulatory momentum, combined with growing collaboration between academic research institutes and contract manufacturing organizations, is accelerating the translation of preclinical candidates into clinical-grade products. As a result, the sector is poised for a new wave of innovation, where precision diagnostics and targeted therapies coalesce to deliver more effective and efficient patient care.

Assessing the Cumulative Impact of 2025 United States Tariffs on Nuclear Medicine Supply Chains, Research Collaboration Dynamics, and Cross-Border Radiopharmaceutical Trade Flows

The introduction of United States tariffs in 2025 has injected fresh complexity into nuclear medicine supply chains, affecting both isotopic materials and imaging equipment imports. As tariffs on critical raw materials and specialized components took effect, manufacturers faced upward pressure on production costs and logistical constraints. This shift has prompted some producers to reconsider sourcing strategies, invest in domestic isotope generation facilities, and pursue vertical integration to mitigate exposure to import levies.

In tandem, collaborative research networks that once relied on seamless transnational exchange of isotopes and consumables are adjusting to new financial and regulatory burdens. Academic and clinical partners in Europe and Asia are exploring local production partnerships to ensure uninterrupted access to critical radiotracers. Meanwhile, equipment providers have intensified after-sales service and spare-parts stocking in regional hubs to circumvent tariff-driven delays. These adjustments underscore a broader rethinking of the global nuclear medicine ecosystem, where supply resilience and cost containment have become as vital as clinical efficacy for sustaining growth and innovation.

Uncovering Key Market Segmentation Insights Across Product Types, Administration Modes, Usage Categories, Clinical Applications, and End User Profiles for Strategic Clarity

Insights into market segmentation reveal a multifaceted framework that underpins strategic planning and resource allocation. Across product types, the field is delineated into diagnostic radiopharmaceuticals-encompassing positron emission tomography isotopes and single photon emission computed tomography isotopes-and therapeutic nuclear medicine, which includes brachytherapy isotopes such as cesium-131, iodine-125, iridium-192 and palladium-103, alongside radiopharmaceutical therapies employing both alpha emitters and beta emitters. This layered breakdown enables targeted analysis of clinical utility, manufacturing complexity, and regulatory pathways.

The mode of administration distinguishes between intravenous injection and oral ingestion, reflecting divergent pharmacokinetic profiles and patient convenience considerations. Usage patterns are classified into diagnostic procedures and therapeutic procedures, with diagnostic workflows segmented by PET scanner modalities-ranging from analog to digital systems-and SPECT scanners designed for high-resolution imaging. Clinical application categories span cardiology, endocrinology, gastroenterology, neurology, oncology, orthopedics and pulmonology, each driving unique demand trajectories based on disease prevalence and standard-of-care protocols. Finally, end users include academic and research institutes, specialized diagnostic centers, and hospitals-which themselves are segmented into government and private facilities-highlighting the varying operational requirements and procurement processes across the healthcare spectrum.

Analyzing Regional Dynamics and Priority Drivers in the Americas, Europe Middle East Africa, and Asia Pacific Markets for Informed Decisions in Nuclear Medicine Expansion Strategies

Regional dynamics in nuclear medicine reflect divergent investment patterns, infrastructure maturity, and regulatory environments across the Americas, Europe Middle East Africa and Asia Pacific. In the Americas, established healthcare systems in North America drive high adoption of advanced imaging platforms and cutting-edge radiotracers, while Latin American markets focus on expanding basic PET and SPECT capacity to address growing diagnostic needs. Stakeholders in this region are balancing the need for cost-effective supply solutions with demand for the latest theranostic protocols.

Europe Middle East Africa presents a mosaic of adoption rates, with Western Europe leading in standardized regulatory frameworks and collaborative research consortia. Emerging markets in the Middle East and Africa are at earlier stages of establishing isotope generation and distribution networks, often leveraging public-private partnerships to accelerate capability building. Regulatory harmonization efforts are underway to reduce complexity for multinational clinical trials and cross-border collaborations.

Asia Pacific's nuclear medicine sector is characterized by rapid capacity expansion in countries such as China, Japan and India, driven by government initiatives to enhance domestic isotope production and bolster nuclear medicine infrastructure. This region is also a hotbed for technological innovation, with local manufacturers investing heavily in digital imaging detectors and mobile cyclotron installations. As a result, Asia Pacific is emerging as both a consumer and producer of advanced radiopharmaceutical solutions.

Profiling Leading Industry Stakeholders and Strategic Partnerships Fueling Innovation, Operational Excellence, and Competitive Advantage in the Nuclear Medicine Value Chain

Leading companies are forging strategic alliances to accelerate pipeline development and reinforce market presence. Global imaging equipment manufacturers have partnered with radiopharmaceutical developers to co-develop end-to-end solutions that optimize scanner performance for novel tracers. Specialized isotope producers are collaborating with contract development and manufacturing organizations to scale up production of targeted alpha and beta emitters, while nuclear pharmacies are expanding their geographic footprint through licensing agreements with hospitals and diagnostic centers.

In parallel, a new generation of agile start-ups is leveraging proprietary radiochemistry platforms to engineer next-generation theranostic agents, often in joint ventures with academic research institutions. These collaborations are fostering a robust innovation ecosystem, where intellectual property is shared under structured agreements to de-risk development and accelerate regulatory submissions. Equally, established pharmaceutical companies are investing in nuclear medicine capabilities through acquisitions, signaling growing recognition of radiopharmaceuticals as a core component of precision medicine portfolios.

Delivering Actionable Recommendations to Empower Industry Leaders in Optimizing Supply Chains, Regulatory Compliance, and Investment Priorities Within Nuclear Medicine Ecosystems

Industry leaders should prioritize diversification of isotope sourcing by investing in regional production capacity and forming consortium-based supply agreements to hedge against geopolitical and trade disruptions. Strengthening regulatory engagement through active participation in standards-setting bodies will help align approval processes across key markets and reduce time-to-clinic for novel compounds. Moreover, integrating advanced data analytics into procurement and inventory management can enhance forecasting accuracy and minimize waste for short-lived isotopes.

Organizations must also consider forging cross-sector alliances with digital health and artificial intelligence specialists to develop companion diagnostic platforms that personalize treatment pathways. Deploying modular cyclotron technologies in strategic locations will not only improve supply resilience but also drive down logistics costs. Finally, dedicating resources to workforce training and safety protocols will ensure that facilities maintain high compliance standards, safeguard staff and patients, and support sustainable growth in an increasingly complex environment.

Detailing Rigorous Research Methodology Employed to Ensure Data Integrity, Comprehensive Market Analysis, and Robust Validation in Nuclear Medicine Market Intelligence

This report's insights are grounded in a rigorous methodology that combines primary and secondary research, data triangulation and expert validation. An extensive review of peer-reviewed publications, patent filings and regulatory databases provided the foundational knowledge base. Detailed interviews were conducted with senior executives across radiopharmaceutical manufacturers, imaging equipment providers, academic research centers and regulatory authorities to capture firsthand perspectives on emerging trends and industry challenges.

Quantitative data sets covering production volumes, technology adoption rates and demographic trends were analyzed using statistical techniques to identify underlying patterns and correlations. Segmentation analysis was applied across product types, administration modes, clinical applications and end-user categories to ensure that findings are granular and actionable. The resulting conclusions were subjected to multiple rounds of expert review to verify accuracy and relevance, ensuring that the final report delivers robust, evidence-based insights for strategic decision making.

Summarizing Critical Findings and Strategic Implications for Stakeholders to Capitalize on Emerging Trends and Navigate the Future of the Nuclear Medicine Sector

The convergence of advanced tracer development, digital imaging breakthroughs and evolving regulatory frameworks is reshaping nuclear medicine into a truly precision-driven discipline. From the impact of 2025 tariffs on supply chain resilience to the nuanced segmentation insights across product types and clinical applications, this analysis underscores the importance of strategic adaptability and collaborative innovation. Regional dynamics further highlight the need for tailored approaches that address local infrastructure, regulatory alignment and market maturity.

Looking ahead, stakeholders who proactively invest in supply diversification, regulatory harmonization and cross-sector partnerships will be best positioned to capture the next wave of opportunities in theranostics and diagnostic imaging. By leveraging the comprehensive findings outlined in this report, decision-makers can refine their go-to-market strategies, optimize resource allocation and accelerate time-to-clinic for transformative nuclear medicine solutions. This confluence of innovation, regulation and strategic foresight will define the sector's trajectory and its impact on patient care in the coming decade.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine Market, by Product Type

  • 8.1. Diagnostic Radiopharmaceuticals
    • 8.1.1. Positron Emission Tomography (PET) Isotopes
    • 8.1.2. Single Photon Emission Computed Tomography (SPECT) Isotopes
  • 8.2. Therapeutic Nuclear Medicine
    • 8.2.1. Brachytherapy Isotopes
      • 8.2.1.1. Cesium-131
      • 8.2.1.2. Iodine-125
      • 8.2.1.3. Iridium-192
      • 8.2.1.4. Palladium-103
    • 8.2.2. Radiopharmaceutical Therapy
      • 8.2.2.1. Alpha Emitters
      • 8.2.2.2. Beta Emitters

9. Nuclear Medicine Market, by Mode Of Administration

  • 9.1. Intravenous Injection
  • 9.2. Oral Ingestion

10. Nuclear Medicine Market, by Usage

  • 10.1. Diagnostic Procedure
    • 10.1.1. PET Scanners
      • 10.1.1.1. Analog PET
      • 10.1.1.2. Digital PET
    • 10.1.2. SPECT Scanners
  • 10.2. Therapeutic Procedure

11. Nuclear Medicine Market, by Application

  • 11.1. Cardiology
  • 11.2. Endocrinology
  • 11.3. Gastroenterology
  • 11.4. Neurology
  • 11.5. Oncology
  • 11.6. Orthopedics
  • 11.7. Pulmonology

12. Nuclear Medicine Market, by End Users

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals
    • 12.3.1. Government Hospitals
    • 12.3.2. Private Hospitals

13. Nuclear Medicine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nuclear Medicine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nuclear Medicine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nuclear Medicine Market

17. China Nuclear Medicine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3B Pharmaceuticals GmbH
  • 18.6. Actinium Pharmaceuticals, Inc.
  • 18.7. B J Madan & Co.
  • 18.8. Bayer AG
  • 18.9. Bracco S.p.A.
  • 18.10. BWX Technologies, Inc.
  • 18.11. Clarity Pharmaceuticals
  • 18.12. Curium
  • 18.13. Eli Lilly and Company
  • 18.14. GE HealthCare
  • 18.15. IBA
  • 18.16. Institute of Isotopes Co., Ltd
  • 18.17. Isotopia Molecular Imaging Ltd.
  • 18.18. Jubilant Pharma Limited
  • 18.19. Lantheus Holdings, Inc.
  • 18.20. Medi-Radiopharma Co., Ltd.
  • 18.21. Nordion
  • 18.22. Northstar Medical Technologies LLC
  • 18.23. Novartis AG
  • 18.24. Nusano, Inc.
  • 18.25. PeptiDream Inc.
  • 18.26. Radiopharm Theranostics Limited
  • 18.27. SHINE Technologies, LLC
  • 18.28. Siemens Healthineers AG
  • 18.29. Sinotau Pharmaceuticals Group
  • 18.30. South African Nuclear Energy Corporation
  • 18.31. State Atomic Energy Corporation Rosatom
  • 18.32. Thor Medical AS by Nordic Nanovector ASA

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 234. GCC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 273. G7 NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. G7 NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 286. NATO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. NATO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 291. NATO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)